Literature DB >> 22078334

Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group.

Christian Winter1, David Pfister, Jonas Busch, Cigdem Bingöl, Ulrich Ranft, Mark Schrader, Klaus-Peter Dieckmann, Axel Heidenreich, Peter Albers.   

Abstract

BACKGROUND: Residual tumor resection (RTR) after chemotherapy in patients with advanced germ cell tumors (GCT) is an important part of the multimodal treatment. To provide a complete resection of residual tumor, additional surgical procedures are sometimes necessary. In particular, additional vascular interventions are high-risk procedures that require multidisciplinary planning and adequate resources to optimize outcome.
OBJECTIVES: The aim was to identify parameters that predict additional vascular procedures during RTR in GCT patients. DESIGN, SETTING, AND PARTICIPANTS: A retrospective analysis was performed in 402 GCT patients who underwent 414 RTRs in 9 German Testicular Cancer Study Group (GTCSG) centers. Overall, 339 of 414 RTRs were evaluable with complete perioperative data sets. MEASUREMENTS: The RTR database was queried for additional vascular procedures (inferior vena cava [IVC] interventions, aortic prosthesis) and correlated to International Germ Cell Cancer Collaborative Group (IGCCCG) classification and residual tumor volume. RESULTS AND LIMITATIONS: In 40 RTRs, major vascular procedures (23 IVC resections with or without prosthesis, 11 partial IVC resections, and 6 aortic prostheses) were performed. In univariate analysis, the necessity of IVC intervention was significantly correlated with IGCCCG (14.1% intermediate/poor vs 4.8% good; p=0.0047) and residual tumor size (3.7% size < 5 cm vs 17.9% size ≥ 5 cm; p < 0.0001). In multivariate analysis, IVC intervention was significantly associated with residual tumor size ≥ 5 cm (odds ratio [OR]: 4.61; p=0.0007). In a predictive model combining residual tumor size and IGCCCG classification, every fifth patient (20.4%) with a residual tumor size ≥ 5 cm and intermediate or poor prognosis needed an IVC intervention during RTR. The need for an aortic prosthesis showed no correlation to either IGCCCG (p=0.1811) or tumor size (p=0.0651).
CONCLUSIONS: The necessity for IVC intervention during RTR is correlated to residual tumor size and initial IGCCCG classification. Patients with high-volume residual tumors and intermediate or poor risk features must initially be identified as high-risk patients for vascular procedures and therefore should be referred to specialized surgical centers with the ad hoc possibility of vascular interventions.
Copyright © 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22078334     DOI: 10.1016/j.eururo.2011.10.045

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  17 in total

Review 1.  Residual tumor resection (RTR).

Authors:  A Lusch; P Albers
Journal:  World J Urol       Date:  2016-12-21       Impact factor: 4.226

2.  Radiotherapy plus chemotherapy versus chemotherapy alone in penile cancer patients with extracapsular nodal extension after inguinal lymph node surgery: a multi-institutional study.

Authors:  Zai-Shang Li; Xue-Ying Li; Bin Wang; Peng Chen; Xiang Li; Ornellas Antonio Augusto; Zi-Ke Qin; Zhuo-Wei Liu; Yong-Hong Li; Hui Han; Fang-Jian Zhou
Journal:  World J Urol       Date:  2020-04-17       Impact factor: 4.226

3.  Preoperative clinical and radiographic predictors of major vascular surgery in patients with testicular cancer undergoing post-chemotherapy residual tumor resection (PC-RPLND).

Authors:  Alessandro Nini; Matthias Boschheidgen; Andreas Hiester; Christian Winter; Gerald Antoch; Lars Schimmöller; Peter Albers
Journal:  World J Urol       Date:  2021-11-03       Impact factor: 4.226

Review 4.  Surgical resection of urological tumor metastases following medical treatment.

Authors:  Axel Heidenreich; Stefan Wilop; Michael Pinkawa; Daniel Porres; David Pfister
Journal:  Dtsch Arztebl Int       Date:  2012-09-28       Impact factor: 5.594

Review 5.  [When is surgical resection of metastases in testicular germ cell tumors indicated and is there a scientific basis?]

Authors:  A Heidenreich; P Paffenholz; F Haidl; D Pfister
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

6.  Post-chemotherapy laparoscopic retroperitoneal lymph node dissection is feasible for stage IIA/B non-seminoma germ cell tumors.

Authors:  Terukazu Nakamura; Akihiro Kawauchi; Masakatsu Oishi; Takashi Ueda; Takumi Shiraishi; Hiroyuki Nakanishi; Kazumi Kamoi; Yoshio Naya; Fumiya Hongo; Koji Okihara; Tsuneharu Miki
Journal:  Int J Clin Oncol       Date:  2015-12-23       Impact factor: 3.402

Review 7.  Testicular cancer.

Authors:  Liang Cheng; Peter Albers; Daniel M Berney; Darren R Feldman; Gedske Daugaard; Timothy Gilligan; Leendert H J Looijenga
Journal:  Nat Rev Dis Primers       Date:  2018-10-05       Impact factor: 52.329

8.  Radiomics allows for detection of benign and malignant histopathology in patients with metastatic testicular germ cell tumors prior to post-chemotherapy retroperitoneal lymph node dissection.

Authors:  Bettina Baessler; Tim Nestler; Daniel Pinto Dos Santos; Pia Paffenholz; Vikram Zeuch; David Pfister; David Maintz; Axel Heidenreich
Journal:  Eur Radiol       Date:  2019-12-11       Impact factor: 5.315

9.  [Postchemotherapy residual tumour resection in complex metastatic sites of advanced testicular germ cell tumours].

Authors:  P Paffenholz; D Pfister; A Heidenreich
Journal:  Urologe A       Date:  2016-05       Impact factor: 0.639

10.  Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer.

Authors:  J Beyer; P Albers; R Altena; J Aparicio; C Bokemeyer; J Busch; R Cathomas; E Cavallin-Stahl; N W Clarke; J Claßen; G Cohn-Cedermark; A A Dahl; G Daugaard; U De Giorgi; M De Santis; M De Wit; R De Wit; K P Dieckmann; M Fenner; K Fizazi; A Flechon; S D Fossa; J R Germá Lluch; J A Gietema; S Gillessen; A Giwercman; J T Hartmann; A Heidenreich; M Hentrich; F Honecker; A Horwich; R A Huddart; S Kliesch; C Kollmannsberger; S Krege; M P Laguna; L H J Looijenga; A Lorch; J P Lotz; F Mayer; A Necchi; N Nicolai; J Nuver; K Oechsle; J Oldenburg; J W Oosterhuis; T Powles; E Rajpert-De Meyts; O Rick; G Rosti; R Salvioni; M Schrader; S Schweyer; F Sedlmayer; A Sohaib; R Souchon; T Tandstad; C Winter; C Wittekind
Journal:  Ann Oncol       Date:  2012-11-14       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.